NMPA Registration vs Self-Declaration: Which China Medical Device Approval Path?
When entering China’s medical device market, overseas manufacturers face a critical choice between two regulatory pathways: full 医疗器械注册 (Medical Device Registration, yīliáo qìxiè zhùcè) through the 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) or the simplified 自我声明 (Self-Declaration, zìwǒ shēngmíng) process. Over 90% of foreign medical devices entering China require full NMPA Registration — a process taking 12 to 48 months and costing between ¥300,000 and ¥2,000,000 depending on device classification. Only Class I (low-risk) devices qualify for the Self-Declaration path, which can be completed in 30 to 60 days at under ¥50,000.
Understanding NMPA Registration (医疗器械注册)
Full NMPA Registration is mandatory for all Class II (medium-risk) and Class III (high-risk) medical devices marketed in China. This pathway requires submission of a comprehensive technical dossier including clinical trial data or a clinical evaluation report (CER), quality management system documentation aligned with GB/T 42061-2022 (the Chinese equivalent of ISO 13485), and product testing reports from NMPA-accredited laboratories. In 2023, NMPA received over 14,000 registration applications and approved approximately 12,634 devices — a 10.8% increase from 2022, reflecting growing market demand.
For Class II devices, the average NMPA review cycle spans 12 to 24 months, while Class III devices typically require 18 to 48 months. Total costs range from ¥300,000 to ¥500,000 for Class II and ¥800,000 to ¥2,000,000 for Class III, covering testing fees, clinical evaluation expenses, regulatory consulting, and administrative charges. A mandatory requirement is the appointment of a 境内代理人 (China Legal Agent, jìngnèi dàilǐ rén) — a registered entity in China that acts as the manufacturer’s regulatory representative and recall point of contact.
Post-approval, NMPA Registration certificates are valid for 5 years and must be renewed with updated documentation. Manufacturers must also comply with ongoing reporting obligations, including adverse event notifications and annual product quality reviews. Failure to do so can result in suspension or revocation of registration.
Understanding Self-Declaration (自我声明)
Self-Declaration is reserved exclusively for Class I medical devices — the lowest risk category — according to China’s Medical Device Classification Directory (《医疗器械分类目录》, yīliáo qìxiè fēnlèi mùlù). Typical Class I devices include adhesive bandages, surgical masks, examination gloves, thermometers, and basic tongue depressors. Rather than submitting a formal dossier for NMPA review, manufacturers file a self-declaration document affirming compliance with applicable Chinese national standards (GB standards) and industry standards (YY standards).
The Self-Declaration process is completed in 30 to 60 days, with total costs typically under ¥50,000. However, manufacturers must still meet all technical and labeling requirements, including Chinese-language labeling and instructions for use (IFU). NMPA retains the right to conduct post-market surveillance audits on any Self-Declared product. If non-compliance is found, penalties include product recalls, fines up to ¥300,000, and potential blacklisting of the manufacturer and its China Legal Agent.
Importantly, the Self-Declaration path does not require clinical evaluation data, on-site quality audits, or renewal of the declaration itself. However, the manufacturer must maintain a quality management system (QMS) that meets GB/T 19001 (ISO 9001) or, preferably, GB/T 42061 (ISO 13485). Local authorities may request documentation at any time. Since 2021, NMPA has increased post-market inspections on Self-Declared Class I devices by 40%, signaling stronger enforcement.
Key Differences Between NMPA Registration and Self-Declaration
| Feature | NMPA Registration | Self-Declaration |
|---|---|---|
| Applicable Device Class | Class II & Class III | Class I only |
| Review Timeline | 12–48 months | 30–60 days |
| Estimated Total Cost | ¥300,000–¥2,000,000 | ¥5,000–¥50,000 |
| Clinical Data Required | Yes (Class II & III) | No |
| On-Site Quality Audit | Yes (Class III, sometimes Class II) | No (post-market only) |
| China Legal Agent Required | Yes (境内代理人) | Yes (境内代理人) |
| Certificate Validity | 5 years (renewable) | Ongoing (subject to audits) |
| Average Annual Compliance Cost (Post-Approval) | ¥100,000–¥500,000 | ¥10,000–¥50,000 |
| Risk of Application Rejection | ~25% (incomplete dossiers) | ~5% (misclassification or standard mismatch) |
The most significant divergence lies in clinical evaluation: NMPA Registration for Class II and III devices typically requires a CER or full clinical trial, whereas Self-Declaration for Class I devices only requires a declaration of conformity with standards. Additionally, NMPA Registration involves a substantive document review + on-site audit cycle, while Self-Declaration is a notification-based process. However, both pathways require a China Legal Agent and GB-standard compliance as prerequisites.
Decision Framework: Which Path Fits Your Device?
If your device is classified as Class I (low risk) according to NMPA’s Medical Device Classification Directory — for example, non-invasive consumables (bandages, gauze), basic diagnostic aids (stethoscopes, thermometers), or manual surgical instruments (scalpels, forceps) — choose Self-Declaration. This path minimizes time, cost, and regulatory complexity while still granting full market access. Ensure your product meets all applicable GB and YY standards, and appoint a reliable China Legal Agent to handle post-market obligations.
If your device is Class II (medium risk) or Class III (high risk) — including implantable devices (stents, hip joints), active therapeutic equipment (ventilators, defibrillators), or in vitro diagnostics (reagents, analyzers) — choose full NMPA Registration. Given the 12 to 48-month timeline and substantial investment, early planning with a qualified regulatory partner is essential. Prepare your technical dossier, GB/T 42061-certified QMS documentation, and clinical evaluation strategy well in advance. Budget for testing, translation, and consulting fees.
If your device’s classification is uncertain — for example, a novel diagnostic aid that could be interpreted as Class I or Class II — choose to obtain an official NMPA classification ruling before submitting any application. Misclassification can lead to application rejection, penalties, and market access delays of 6–12 months. A formal classification determination costs approximately ¥10,000–¥30,000 and takes 2–3 months, but it provides legal certainty.
3 Common Pitfalls in China Device Approval
NEXT STEPS
- Determine your device’s NMPA classification — Read our complete NMPA Classification Guide for Medical Devices (Class I, II, III) to know which path applies before you invest time or money.
- Choose the right approval pathway — Compare Self-Declaration vs full Registration in our step-by-step NMPA approval guide with timelines, costs, and documentation checklists.
- Engage a qualified China regulatory partner — Contact our China medical device team for a pathway assessment and project roadmap tailored to your device class, product type, and market timeline.
— China Gateway 360 —
Remote China market entry support, built around execution.
